Legal Representation
Attorney
Nicole B. Rackiewicz
USPTO Deadlines
Application History
22 events| Date | Code | Type | Description |
|---|---|---|---|
| Sep 12, 2022 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED |
| Sep 12, 2022 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Feb 1, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Jan 28, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Jan 28, 2022 | EXT1 | S | SOU EXTENSION 1 FILED |
| Jan 28, 2022 | EX1G | S | SOU EXTENSION 1 GRANTED |
| Aug 10, 2021 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Jun 15, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Jun 15, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| May 26, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| May 10, 2021 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
| May 10, 2021 | GNEA | O | EXAMINERS AMENDMENT E-MAILED |
| May 10, 2021 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| May 10, 2021 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
| May 10, 2021 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| May 3, 2021 | CPRA | R | PRIORITY ACTION WRITTEN |
| May 3, 2021 | GPRA | F | PRIORITY ACTION E-MAILED |
| May 3, 2021 | GPRN | O | NOTIFICATION OF PRIORITY ACTION E-MAILED |
| Apr 23, 2021 | DOCK | D | ASSIGNED TO EXAMINER |
| Jan 14, 2021 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Jan 13, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Nov 17, 2020 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Pharmaceutical products for the prevention and treatment of cancer; Therapeutic pharmaceuticals for the treatment of cancer, cardiovascular diseases, metabolic diseases, musculoskeletal diseases, infectious diseases, and neurodegenerative diseases; Pharmaceutical preparations for the treatment of hyperlipidemia; Local anesthetics; Drug delivery agents in the form of a coating for tablets and capsules that facilitate the delivery of a wide range of pharmaceuticals; Medicinal preparations of the treatment of infectious diseases and for use in oncology; Anesthetics; Anesthetics for surgical purposes; Pharmaceutical preparations for treating diabetes; Anti-diabetic pharmaceuticals; Cardiovascular agents for medical purposes; Drug delivery agents in the form of transdermal patches, coatings for tablets, and synthetic materials that facilitate the delivery of pharmaceutical preparations; Skeletal muscle relaxants; Pharmaceutical preparations for treating hypertension; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations for the treatment of cancer, cardiovascular diseases, metabolic diseases, musculoskeletal diseases, infectious diseases, and neurodegenerative diseases; Anesthetics for surgical and non-surgical use; Pharmaceuticals, namely, lipid lowering agents; Pharmaceutical preparations for use in chemotherapy; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders; Transdermal patches for use in the treatment of neurodegenerative disease; Cardiovascular pharmaceuticals; Hypolipidemic agents; Anesthetics for surgical use; Pain relief medication; Pharmaceutical products for the treatment of cancer; Hypolipidemic agents
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Design Mark
The mark consists of the stylized words "OEP Pharma" to the right of a miscellaneous design having an overall diamond shape.
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"PHARMA"
USPTO Documents
Loading USPTO documents...